Chemotherapy + Imatinib
Phase 2Small molecule
Chemotherapy + Imatinib is one of 33 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Zyloprim
Alnylam PharmaceuticalsPhase 3
Iclusig
TakedaPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Arranon
NovartisPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Newly Diagnosed1 trial
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Active, not recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 3·NCT04722848·236 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Chemotherapy + Imatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details